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Abstract
Background: Human papillomavirus DNA detection in head and neck squamous cell carcinoma has been linked to
improved patient prognosis. The main aims of the study was to test the hypotheses that HPV16 E6/E7 oncogene
and p53 function within tumours were associated with the widely reported improved patient survival and
prognosis in head and neck cancer.
Methods: HPV16 DNA, mRNA and p53 mRNA presence were analysed in a prospective study of 42 unselected
HNSCC patients; correlating the data with patient age, tumour staging/grade, treatment response, disease
recurrence and survival.
Results: HPV16 DNA and HPV16 mRNA were present in 45.2 % and 21.4 % of patients, respectively. There was a
significant positive association between the detection of HPV16 E6/E7 mRNA and p53 mRNA (p = 0.032), but this
was not replicated for HPV16 DNA. Five-year disease free survival for the whole cohort was 63 % (CI 52.5–73.5 %).
Multivariable analysis revealed only HPV16 E6/E7 mRNA expression to have significant prognostic influence (p = 0.04).
Conclusions: Our study suggests that HPV16 oncogenic transcriptional activity within HNSCC tumours is associated
with improved patient survival and better prognosis in a German population. Simple HPV DNA detection alone did
not demonstrate this association. The significant association of full-length (wild-type) p53 with HPV16 E6/E7 mRNA is
further evidence for a functional relationship, which could contribute to the widely reported improved survival and
prognosis. Larger studies are required to validate the frequency of HPV16 mRNA expression in HNSCC.
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Background
Head and neck squamous cell carcinoma (HNSCC), with
a worldwide incidence rate of approximately 500,000
new diagnoses per annum, is the 6th most common form
of cancer [1]. Mortality has not improved substantially
over the last few decades [2], due to late diagnosis (75 %
of cases) and/or recurrent primary malignancies, and
remains at 40–50 % at 5 years [3, 4]. Risk factors for
the development of HNSCCs include tobacco and al-
cohol use as well as oral human papillomavirus (HPV)
infection [5].
Human papillomavirus (HPV) has an important patho-
genic role for a subset of HNSCC [5–8], leading to the
grouping of oropharyngeal tumours into HPV-negative
and HPV-positive cancers. Meta-analyses have been used
to assess the potential worldwide prevalence of HPV in
HNSCC, resulting in an estimate of 26–35.4 % [7, 8]. A
recent systematic review of oropharyngeal subsite cancers
and HPV prevalence found a significant increase when
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comparing studies recruiting patients before 2000 and
after 2005 respectively (40.5 % [CI 35.1–46.1 %] versus
72.2 % [CI 52.9–85.7]) [9].
HPV status of HNSCC has been shown to affect overall
patient prognosis, HPV-positive tumours have an im-
proved response to therapy as reflected in a significant
reduction in the risk of progression and improvement
in overall survival rate compared to HPV-negative ma-
lignancies, irrespective of the treatment regime used
[10–13]. However, a certain number of patients with
HPV-positive tumours have similar clinical outcomes
to those seen in HPV-negative disease, the latter being
linked to other prognostic factors such as increased
EGFR expression [14] or smoking status [15].
As the fraction of HPV-positive head and neck cancers
increases, this may highlight the importance of under-
standing the underlying mechanisms responsible for
oncogenesis and the differences between HPV-related
and HPV-unrelated disease that determine clinical out-
come [16, 17].
The detection of HPV DNA alone, in the absence of
evidence for viral gene expression, is not unequivocal
molecular evidence that HPV infection either causes or
promotes malignant progression in a lesion. In order to
address this point, we have used a highly sensitive PCR
detection method, together with a commercially avail-
able HPV genotyping kit (Linear Array HPV genotyping
test, Roche Diagnostics Ltd., UK), to determine the pres-
ence of high- and low-risk HPV subtype L1 DNA in
HNSCC tumours. Furthermore, we employed a separate
PCR assay to detect HPV16 E6/E7 DNA and mRNA
expression [18]. The ability of HPV 16 E6 to bind and
promote the degradation of p53 has been suggested as
one reason for an absence of disruptive p53 mutations
in HPV 16 positive HNSCCs [19]. Full-length p53 RNA
expression was therefore examined in age-matched groups
of HPV16 E6/E7 expressing and non-expressing tumours.
Patient data was collected, including patient age, sex,
tumour staging, treatment response, recurrence and
mortality. The relationship between the detection of
HPV DNA, RNA, p53 expression and clinical data was
then analysed. To further investigate discordant results,
subgroup analysis was undertaken utilizing p16INK4a
immunohistochemistry.
Although p16INK4A is the most commonly used bio-
marker for HPV positive head and neck cancer, specific
limitations need to be observed. There is a subgroup of
HPV- HNSCCs where expression of p16INK4A could lead
to erroneous classification as HPV positive. Immunohisto-
chemical staining itself can produce false positives i.e.
intra-observer/inter-observer variation of background
stain. In addition, a small but significant cohort of the false
positive HPV- samples have p16INK4A mutations that may
account for accumulation of inactive p16INK4A [15].
Methods
Patients and specimens
Clinical samples were obtained from unselected patients
attending the Bielefeld Academic Teaching Hospital, De-
partment of Otorhinolaryngology, Bielefeld, Germany
between 2008 and 2009. All patients gave written in-
formed consent for the study, which was approved by
the local research ethics committee (Ethik-Kommission
der Ärztekammer Westfalen-Lippe). A sample of the
tumour was taken for histological analysis and the remain-
der was snap-frozen in liquid nitrogen and transported to
the UK on dry ice prior to DNA and RNA extraction. A
consultant histopathologist with expertise in head and
neck pathology reviewed each tissue block to ensure ad-
equate tumor sampling. All experiments were performed
in the Department of Pathology at the University of
Cambridge.
The study comprised 42 HNSCC tissue samples (patient
mean age = 62.9 years, 95 % CI 59.11–66.01, range 46–87).
Tumour staging was classified using the TNM classification
of malignant tumours [20]. Post-operative follow-up was
conducted at regular intervals for a period of five years,
assessing response to treatment, disease recurrence and pa-
tient mortality. Clinical and histopathological features of
the 42 HNSCC patients are shown in Table 1.
DNA extraction
Samples (max. 25 mg) were disrupted in a Bullet
Blender™ (Next Advance, Averill Park, USA) in 300 μl
digestion mix (10 mM Tris, pH 7.5; 10 mM EDTA;
0.5 % SDS; 200 μg/ml Proteinase K) for 5 min and then
incubated overnight at 37 °C. Following Proteinase K in-
activation at 56 °C for 10 min, the lysate was subjected
to a phenol:chloroform extraction (1:1:1 volume) and the
DNA precipitated from the supernatant with 1 ml 100 %
ethanol. The DNA was then centrifuged (13,000 rpm, 4 °C,
20 min), the pellet washed with 70 % ethanol, air dried and
re-suspended in 200 μl PBS. RNase digestion and total gen-
omic DNA isolation was then performed using the DNeasy
Blood and Tissue Kit (QIAGEN Ltd, UK), according to the
manufacturer’s instructions. DNA was eluted with purified
(deionised, double-distilled) H2O, and after purity and
concentration were ascertained using a Nanodrop™ 1000
spectrophotometer, stored at −20 °C until use.
RNA extraction and cDNA synthesis
Samples (max. 25 mg) were disrupted in a Bullet Blender™
(Next Advance, Averill Park, USA) in 400 μl TRIzol re-
agent (Invitrogen Ltd, UK) for 5 min. A further 600 μl of
TRIzol was added to each sample and the lysate subjected
to a chloroform extraction (200 μl). The supernatant
was precipitated with 0.5 ml isopropanol o/n at −20 °C.
The RNA was then centrifuged (13,000 rpm, 4 °C,
20 min), the pellet washed with 70 % ethanol, air dried
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and re-suspended in 50 μl H2O. DNase I digestion
(Invitrogen Ltd, UK) was then performed prior to RNA
clean-up using a PureLink™ RNA Mini Kit (Invitrogen
Ltd, UK), according to the manufacturer’s instructions.
RNA was eluted with purified (deionised, double-distilled)
H2O, purity and concentration was ascertained using a
Nanodrop™ 1000 spectrophotometer.
Up to 5 μg of total RNA was reverse transcribed using
BioScript Reverse Transcriptase (Bioline Ltd, London, UK)
according to the manufacturer’s instructions. Briefly, RNA
was incubated with random primers (Invitrogen Ltd, UK)
at 70 °C for 5 min before being placed on ice for 5 min.
Following the addition of reaction buffer, dNTPs and re-
verse transcriptase, cDNA synthesis was performed under
the following conditions: 25 °C for 5 min, 42 °C for 30 min
(synthesis step) and 70 °C for 10 min (stops reaction).
Samples were stored at −20 °C prior to use. Reverse tran-
scriptase negative samples acted as negative controls for
subsequent analyses.
PCR methods
L1 single step DNA PCR analysis
A PCR assay using the PGMY09/11 L1 consensus pri-
mer set was performed as described previously [21]. The
PCR cycling conditions were as follows; denaturing step
of 95 °C for 5 min, followed by 40 cycles of 95 °C for
1 min, 55 °C for 1 min and 72 °C for 1 min. This was
followed by a final extension period of 10 min at 72 °C.
Agarose gel electrophoresis was used to confirm the
presence/absence of bands specific for both HPV and
human β-globin. Human placental DNA (Sigma-Aldrich,
UK), containing 1000 copies of the plasmid pSP64-
HPV16 [22], was used as a positive control for this and
subsequent HPV16 PCRs of genomic DNA.
L1 nested DNA PCR and direct cycle sequencing
PCR reactions that were negative following amplification
with the PGMY09/11 L1 consensus primers were sub-
jected to further PCR amplification using the GP5+/GP6+
primer pair as described previously [23]. The PCR cycling
conditions were as follows; denaturing step of 95 °C for
5 min, followed by 30 cycles of 95 °C for 1 min, 40 °C for
2 min and 72 °C for 1.5 min. This was followed by a final
extension period of 10 min at 72 °C.
Positive bands identified following agarose gel electro-
phoresis were excised, the DNA purified using QiaQuick
Gel Extraction columns according to the manufacturer’s
instructions (QIAGEN Ltd, UK) and sequenced directly
(Geneservice Ltd, UK) using the GP5+/GP6+ primers.
The sequences were then aligned with known HPV types
(NCBI Basic Local Alignment Search Tool).
PGMY-line blot assay/Linear Array HPV genotyping test
The procedure was carried out according to the manu-
facturer’s instructions and as previously described [24].
Briefly, PCR amplification was carried out with LA HPV
GT primers as provided: Each 100 μl reaction consisted
of 50 μl working master mix containing MgCl2, KCl,
Amplitaq Gold DNA polymerase, uracil-N-glycosilase,
Table 1 Clinical, histopathological and follow-up data for 42
HNSCC patients
Variable Number Percent
Site Larynx 16 38.1
Oropharynx 15 35.7
Hypopharynx 5 11.9
Oral cavity 4 9.5
Otherb 2 4.8










M stagea 0 40 92.9
1 0 4.8
X 2 2.4





Treatment RT 13 30.9
CRT 2 4.7
Death Yes 9 21.4
No 33 78.6




Recurrence Yes 13 30.9
No 29 69.1
T represents size or direct extent of the tumour, N the degree of lymph node
spread and M the presence of metastases
aPathological TNM staging; bTwo patients had primary SCC located in EAC;
RT, primary radiotherapy; CRT, primary chemoradiotherapy; cPost-treatment
clinical evaluation was undertaken at ~8-12 weeks [complete response is
defined as the disappearance of all detectable disease at the primary site on
visual inspection and/or imaging; partial response was defined as tumour
reduction by >50 %]
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deoxynucleotides (dNTPs) and biotinylated PGMY and
β-globin primers together with 50 μl of DNA sample.
DNA templates were titrated to a concentration of 2–
4 ng/μl, i.e. 100–200 ng template DNA per reaction. The
Applied Biosystems gold-plated 96-Well GeneAmp PCR
System 9700 was programmed as follows: 50 °C for
2 min, 95 °C for 9 min and 40 cycles of 95 °C for 30 s,
55 °C for 1 min, 72 °C for 1 min and finally, at 72 °C for
5 min before holding indefinitely at 72 °C. The 40 cycles
had a ramp rate set at 50 %.
The amplicons were denatured and hybridised to a
strip containing specific probes for 37 HPV genotypes
and β-globin reference lines before undergoing stringent
washes.
Colorimetric determination with a Linear Array Detec-
tion Kit: the colour change reaction was from streptavidin-
horseradish peroxidase mediated precipitation of working
substrate. Positive reactions appeared as blue lines on the
strip. The strips were interpreted using the HPV reference
guide provided.
E6/E7 DNA PCR analysis
A PCR assay using primers specific for HPV16 E6/E7
was performed as described previously [25]. The PCR
cycling conditions were as follows; denaturing step of
94 °C for 5 min, followed by 40 cycles of 94 °C for
1 min, 60 °C for 45 s and 72 °C for 1 min. This was
followed by a final extension period of 10 min at 72 °C.
E6/E7 cDNA PCR analysis
cDNA generated from extracted HNSCC mRNA was
subjected to E6/E7 PCR analysis using the same primers
and conditions as used for DNA samples. Expected
amplicon sizes were as follows; unspliced RNA, 406 bp:
E6*I, 224 bp: E6*II, 107 bp. A PCR for GAPDH was
performed, to confirm that the RNA was suitable for
amplification, using primers that have been previously
described [26]. The PCR cycling conditions were as fol-
lows; denaturing step of 95 °C for 5 min, followed by
40 cycles of 95 °C for 1 min, 60 °C for 1 min and 72 °C
for 1 min. This was followed by a final extension period
of 5 min at 72 °C.
p53 cDNA PCR analysis
p53 amplification was performed on 9 HNSCC samples
in which E6/E7 transcripts had been successfully amplified
(mean age 63.7 years, 95 % CI 57.41–69.93, range 50–74),
together with 12 HNSCC where no E6/E7 transcripts were
detectable (mean age 63.2 years, 95 % CI 57.83–68.87,
range 46–78). Following unsuccessful amplification of full-
length p53 using established primers [27], possibly as a re-
sult of RNA fragmentation or degradation, five primer
pairs were designed to span the entire open reading frame.
PCR was carried out on an Applied Biosystems Veriti
using Platinum Taq polymerase (Invitrogen Ltd, UK) and
comprised 1x Platinum Taq buffer, 1.5 mM MgCl2,
200 μM each dNTP, 200 nM each primer, and 1 U of Plat-
inum Taq polymerase in a 50 μl reaction. The PCR cycling
conditions for all primer pairs were as follows; denaturing
step of 94 °C for 2 min, followed by 40 cycles of 94 °C for
1 min, 55 °C for 1 min and 72 °C for 1 min. This was
followed by a final extension period of 10 min at 72 °C.
cDNA generated from primary human foreskin keratino-
cytes was used as a positive control in this assay.
Immunohistochemistry analysis
p16INK4a protein is an inhibitor of cyclin dependent kinase
and has increased expression with elevated levels of HPV
E7. Selected FFPE sections (5 μm) were deparaffinized and
antigen target retrieval was performed with citrate-buffer
boil (0.1 M Sodium Citrate and 0.1 M Citric acid). Immu-
nohistochemistry was performed as previously described
using a mouse monoclonal antibody (BD Biosciences,
USA [18].
Statistical analysis
Statistical calculations were performed using SPSS
Version 17 (Chicago, IL, USA). Significance of the as-
sociation between the detection of HPV16 L1 DNA,
HPV16 E6/E7 DNA, HPV16 E6/E7 mRNA, p53 mRNA
and P16INK4a was calculated using a two-sided Fisher’s
exact test. A Student’s t-test was used to compare mean
ages. Rates of disease-specific and disease free survival
were estimated by means of the Kaplan–Meier method
and were compared by the log-rank test. Univariable and
multivariable models were developed using Cox regression
to investigate size of tumor, nodal status, smoking (never,
current or former if smoking cessation >10 years), adju-
vant chemoradiotherapy, age, histological differentiation,
primary subsite, HPV and p53 status as potential pre-
dictors of outcome. Time dependent co-variants were
investigated to identify concordance with the proportional
hazards assumption.
Results
Detection and identification of HPV L1 sequences
Sensitive detection of HPV L1 sequences was performed
using a combination of PGMY09/11, Linear Array HPV
genotyping test and nested PCR approaches, as previ-
ously described [18]. PGMY09/11 PCR detected HPV in
2/42 samples (4.8 %), Linear Array in 10/42 samples
(23.8 %) and the nested PCR approach in 29/42 samples
(69.0 %). Direct sequencing confirmed the HPV types
detected from PGMY09/11 and GP5+/GP6+ nested PCR
approaches. Combined results from L1 detection methods
showed the presence of HPV 6 in 9/42 (21.4 %) and HPV
16 in 19/42 (45.2 %) samples. Other HPV sequences were
detected in 7 samples, but remained unidentifiable due to
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mixed sequencing traces. HPV 11, HPV 26 and HPV 40
were each found on one occasion in the external meatus,
tonsil and oral cavity regions respectively. The distribution
of the HPV type 16 can be seen in Table 2. There was no
evident association between the detection of HPV 6 or 16
DNA and tumour site.
Detection of HPV16 E6/E7 DNA and mRNA
HPV16 E6/E7 DNA was detected in 21/42 samples
(50 %). There was a significant association between the
detection of HPV16 by E6/E7- and L1-based PCR detec-
tion methods (p = 0.0016, two-sided Fisher’s exact test).
HPV16 E6/E7 transcripts were detected in 9/42 samples
(21.4 %). No significant association was seen between
the presence of HPV16 L1 DNA and E6/E7 transcript
detection (p = 1) or the presence of HPV16 E6/E7
DNA and E6/E7 transcript detection (p = 1). Of the
samples expressing HPV 16 E6/E7, the primary lesion
was located in the larynx (x6), hypopharynx (x1), oro-
pharynx (x1) and oral cavity (x1). There was no associ-
ation between anatomical location and HPV16 E6/E7
expression.
Clinical evaluation and follow-up
Forty-two patients with primary HNSCC were recruited
to this study with a 5-year disease specific survival of
72 % (95 % CI 66–76 %). At the time of surgery, the
mean patient age was 62.9 years (range 46–87). The median
follow-up time was 53 months (range 45–61 months).
Expression of HPV16 mRNA E6/E7 was found to be a
significant predictor of disease free survival on univari-
able analysis but this was not the case when stratifying
by presence of HPV16 L1 or E6/7 DNA (Figs. 1 and 2).
Disease specific survival shows the same clear trend but
does not quite achieve significance. Multivariable analysis
investigated the influence of tumour size (T1-2 versus
T3-4), nodal status, smoking, primary surgery, primary
radiotherapy, primary surgery + adjuvant radiotherapy,
age, histological differentiation (well/moderate/poor
SCC) and subsite. Forward model selection confirmed
mRNA expression as an independent prognostic factor
(Table 3).
There was no significant difference in the mean age,
irrespective of the method of HPV detection used, be-
tween HPV-positive and HPV-negative patients.
Detection of p53 mRNA
Amplicons spanning the entire open reading frame of
p53 were detected in 6/9 (66.7 %) of HPV16 E6/E7
transcript positive HNSCC samples but only in 2/12
(16.7 %) of the age-matched control group, where E6/E7
transcripts were undetectable (Table 4). There was a
significant association between E6/E7 expression and
the presence of full-length p53 (p = 0.032, Fisher’s exact
test; OR 10). Full-length p53 expression was not found
to correlate with anatomical site, HPV16 L1/E6/E7
DNA or p16INK4a.
Discussion
In this study, we report the prevalence of HPV16 DNA
and mRNA in 42 unselected HNSCC patients, significantly
correlating the presence of HPV16 mRNA expression with
the successful amplification of p53 (despite a small sample
size). Overall, HPV16 DNA was present in 45.2 % of sam-
ples, with detectable E6/E7 mRNA in 21.4 %. In two-thirds
of the samples expressing E6/E7, p53 expression was also
seen. This study has enabled the classification of HNSCCs
into subsets based on both their HPV 16 DNA and mRNA
status.
HPV16 and HPV6 were the predominant subtypes
detected, being present in 47.6 % and 21.4 % of the
samples, respectively. Meta-analysis has revealed that
HPV16 is present in the majority of HPV-positive
HNSCCs, with HPVs 18, 6 and 11 involved to a lesser
extent and an overall prevalence of HPV in HNSCC of
25.9 % 27. Large epidemiological studies also suggest
that the oropharyngeal site is most associated with
high-risk oncogenic HPV subtypes [28, 29].
The higher HPV prevalence observed in this series
may be due to the combined use of both sensitive PCR
approaches and a commercial assay (Roche Linear Array
HPV genotyping test) for the detection of HPV sequences.
However, several studies within the meta-analysis found a
comparable prevalence, indicating that our findings are
within the expected range. There were no cases of HPV
Table 2 Distribution of HPV16 in HNSCCs at different anatomical locations
Anatomical site HPV16 L1 DNA Percent HPV16 E6/E7 DNA Percent
Larynx (n = 16) 6 37.5 8 50
Oropharynx (n = 15) 9 60 9 60
Hypopharynx (n = 5) 2 40 1 20
Oral cavity (n = 4) 2 50 3 75
Other (n = 2) 0 0 0 0
Total (n = 42) 19 100 21 100
There was no association between the detection of HPV16 DNA and tumour site
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18 positive HNSCC in our study. The predominance of
HPV 18 in adenocarcinomas of the cervix indicates a
tropism towards glandular tissue [30, 31]. In the con-
text of HNSCC, adenocarcinomas are rare and occur
mainly in the salivary glands [32]. No cases of adeno-
carcinoma were present in this study. The DNA of
HPV 26 and HPV 40 were each found on one occasion.
HPV 26 has been classified as a probable high-risk type,
whereas HPV 40 is a low-risk type [33]. A clear correl-
ation existed between the detection of HPV 16 DNA by
L1- and E6/E7-specific PCRs. However, despite 32 sam-
ples being concordant, it is noted that 10 samples were
positive in one of the PCRs only. This is important for
both the estimation of the overall contribution of HPV
to HNSCC carcinogenesis and to suggest ‘indirect’
mechanisms by which lesions may arise. The detection
of HPV L1 sequences, by Linear Array or PCR amplifi-
cation, is frequently performed and used as an indicator
of HPV-related disease. This has allowed classification
of HNSCC tumours into HPV-positive and HPV-negative
groups. Several studies have documented significantly bet-
ter overall outcome in HNSCC patients with tumours
positive for HPV DNA compared to their HPV-negative
counterparts [9–11, 34].
Fig. 1 Disease free survival (DFS)† stratified by HPV mRNA/DNA (Log- Rank multiple regression analysis p = 0.04 and p = 0.68, respectively)
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Fig. 2 Disease specific survival (DSS)† stratified by HPV mRNA/DNA (Log- Rank multiple regression analysis p = 0.17 and p = 0.66 respectively)
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One of the most significant findings from this study is
that p16 positivity does not correlate with HPV E6/E7
mRNA expression. p16INK4A immunohistochemistry out-
comes are classified as positive or negative depending on
a variable spectrum of detection (ranging from true
negative to background staining to false positive to true
positive). A systematic review by Grønhøj Larsen et al. [35]
identified thirty-nine different studies published between
January 1980 to October 2012 which reported sensitivity
and specificity of p16 detection (with respect to HPV detec-
tion of DNA by PCR). The results ranged from 73 % to
100 % for sensitivity, and 46 % to 100 % for specificity.
The definition of “positive” overexpression of p16 is
also determined by different % staining cut-off levels such
as ≥ 5 %, ≥5 % but ≤ 70 %, ≥70 %, ≥75 % or even less spe-
cific verbal definitions such as “diffuse and strong nuclear
cytoplasmic staining”. There are also no standardisations
of the anti-p16 monoclonal antibodies used and different
clones have different staining avidities and consequently
sensitivities and specificities. Our study used a definition
of staining ≥70 % of cell cytoplasm and nuclei, seen per
field, which stained strongly with the antibody.
This study demonstrates a significant correlation be-
tween HPV status and prognosis, but this was restricted
to mRNA expression alone. Although this information is
important, recent studies suggest further biomarkers
may also be required as a subset of the HPV-positive co-
hort can respond in a manner normally associated with
HPV-negative tumors [16, 17]. It is conceivable that
HNSCCs positive for L1 but negative for E6/E7 DNA
have lost the selective pressure to retain oncogene
Table 3 Log-Rank analysis for disease free survival (DFS) and
disease specific survival (DSS)
Variable DFS p-value DSS p-value




Tumour size (T1-2 versus T3-4) 0.3 0.45
Smoking (Y/N) 0.68 0.51
Surgery 0.72 0.65
Radiotherapy (RT) 0.19 0.62
Surgery + adjuvant RT 0.34 0.26
Age 0.25 0.79
Histology SCC (Well / Mod / Poor) 0.64 0.78
HPV16 E6/7 mRNA 0.04 0.17
HPV16 L1 or E6/7 DNA 0.68 0.66
P53 (full-length) 0.89 0.17
Table 4 p53 detection analysis
Sample ID Anatomical site L1 DNA HPV 16 E6/E7 DNA HPV 16 mRNA p53 PCR Smokers
2 Oropharynx 6 – – – +
5 Larynx 16 – – – –
7 Hypopharynx – – – – +
8 Other – – – – +
9 Oropharynx 6, 16 – – – +
12 Other 6, 11 – – – –
17 Oropharynx Mixed – – – +
18 Larynx – – – – +
26 Larynx 6 – – + –
39 Oropharynx 16 – – + –
50 Oropharynx 16 + – – +
52 Hypopharynx 16 + – – –
10 Larynx 6 – + – –
14 Larynx – – + – +
15 Larynx – + + – –
16 Oral cavity 40 – + + –
33 Larynx 16 + + + +
35 Hypopharynx 16 – + + –
36 Larynx 16 + + + +
41 Oropharynx 16, mixed + + + –
54 Larynx – – + + –
Amplicons spanning the entire p53 open reading frame were amplified from 6/9 HPV 16 E6/E7 mRNA positive HNSCCs (bottom), but only 2/12 transcript negative
samples (top) (p = 0.032, Fisher’s exact test; OR 10). HPV16 DNA or P16INK4a showed no relationship with p53 PCR
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expression following other genomic events. Conversely,
HNSCCs that are E6/E7 positive may have lost L1 se-
quences, for example following integration, making L1
detection unreliable in determining the role of HPV in-
fection at the time of diagnosis.
The detection of viral oncogene transcripts remains
the gold standard by which tumours are classified as HPV
positive [36]. In our study, transcript analysis revealed
21.4 % of samples expressed HPV16 E6/E7 mRNA. Al-
though the patients with HPV16 DNA positive tumours
tended to be younger (mean age for HPV L1 DNA positive
v negative: 60.4 v 64.9 years; mean age for HPV 16 E6/E7
DNA positive v negative: 60.3 v 65.4 years), there was no
difference in age between patients with E6/E7 mRNA
positive tumours and their mRNA negative counterparts
(mean age 63.7 v. 62.6 years). The detection of L1 and
E6/E7 DNA in the absence of E6/E7 mRNA expression
may reflect virus present as either a passenger or as la-
tent infection whereas the presence of E6/E7 mRNA
provides strong molecular evidence for ongoing HPV
transcription (and by implication, translation into proteins),
which caused or promoted malignant progression in the
lesion. HPV-associated cervical carcinomas commonly have
integrated HPV genomes in a single copy [37–39]. There-
fore, a tumour containing transcriptionally active HPV may
well have multiple copies of mature mRNA transcribed
from a single copy of HPV DNA. An actively transcribed
gene can have mRNA copy numbers several orders of mag-
nitude higher than the DNA from which it originates. This
may explain our findings that 4 of the samples were mRNA
positive but DNA negative i.e. reflecting insufficiently sensi-
tive DNA detection assays. Sotlar et al. have previously
quantified the sensitivity of RT-PCR against DNA-PCR for
HPV E6/E7; their data suggest a benefit in favour of the
former test with a ten-fold increased detection rate for
HPV16 subtype [25].
HPV status, as determined solely by DNA-based de-
tection methods, may be insufficient to predict patient
response to treatment and overall outcome. Our study
shows that a proportion of HPV DNA positive tumours
contain transcriptionally active genomes and this may
have more important clinical significance. Other potential
prognostic markers, in addition to extensive tobacco and
alcohol use, include mutation/over-expression of p53,
elevated EGFR levels and over-expression of cyclin D
(CCND1) [40, 41]. p53 expression analysis revealed a
significant association between HPV 16 E6/E7 expres-
sion and the presence of full-length p53. Many studies
have revealed inverse correlations between disruptive
p53 mutations and HPV in HNSCC [6, 27, 42], muta-
tion of p53 has been shown to result in mis-splicing of
transcripts [27, 35, 43] and this may explain the partial
amplification seen in the HPV negative samples analysed.
However, as a significant number of p53 mutations do not
affect full-length expression, this observation may not
readily explain all the findings in this study [44]. An alter-
native method of analysis that may elucidate this in future
studies would involve direct sequence analysis of theTP53
gene (exons 5–9) [45]. HPV positive tumours characteris-
tically have wild-type p53; mutations in p53 are not re-
quired for tumour development because high-risk HPV
E6 targets p53 for degradation [46]. Defects in apoptosis
associated with mutated p53 can potentially lead to treat-
ment resistant tumours and may partly explain the im-
proved response seen in HPV associated disease [47].
The five-year clinical observation period for this study,
in combination with other studies [48–50], suggests the
need to place HPV16 mRNA status as the preferred
stratification modality when designing future treatment
regimes or clinical trials. This has particular importance
when we consider the trend towards “de-intensification”
of existing chemotherapeutic regimes in order to decrease
treatment related co-morbidity [6, 46, 51].
Conclusions
In conclusion, the evidence from this small study suggests
that HPV status, as determined solely by DNA-based de-
tection methods, is insufficient to predict patient response
to treatment and overall outcome in a German population.
Our data supports the hypothesis that HPV positive tu-
mours containing transcriptionally active genomes are a
more reliable indicator of disease free survival than HPV
DNA detection alone. Therefore larger studies are re-
quired to establish the frequency of HPV16 mRNA ex-
pression in HNSCC. This will determine whether this
group, with or without p53 expression, represents a subset
of tumours that have improved treatment response.
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